Based on a licence from Else Marit Inderberg and Sebastien Wälchli’s group at The Section of Cell Therapy at Oslo University Hospital, the company Zelluna Immunotherapy is developing natural killer cells that are steered by T cell receptors. The aim is to offer different forms of targeted immunotherapy treatments that do not have to be individually tailored for each patient. Zelluna Immunotherapy receives NOK 83 million from investors and the Research Council of Norway to continue its work on this new form of cancer immunotherapy.
Published in major journals, first or last author from Oslo University Hospital.
Age Inherently Links to Histology to Define Histoprognostic Classification of Peripheral Neuroblastic Tumors
J Clin Oncol, JCO2001839 (in press)
Imaging predictors of response to cardiac resynchronization therapy: left ventricular work asymmetry by echocardiography and septal viability by cardiac magnetic resonance
Eur Heart J (in press)
Liver transplantation for secondary liver tumors: the difficult balance between survival and recurrence
J Hepatol (in press)